Clinical Significance of Circulating Tumour Cells in Resectable Lung Cancer Patients
NCT ID: NCT05619562
Last Updated: 2022-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
166 participants
OBSERVATIONAL
2009-01-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
NCT06016569
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
NCT02380196
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
NCT01052818
Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer
NCT03724500
Circulating Tumor Cells in Lung Cancer
NCT01658332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Device for CTC/DTC detection
The CTCs/DTCs will be detected and counted in peripheral blood, tumour draining blood and bone marrow samples.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Institute of Molecular and Translational Medicine, Czech Republic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marian Hajduch, M.D., Ph.D.
IMTM director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marian Hajduch, MD, PhD
Role: STUDY_DIRECTOR
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Olomouc
Olomouc, Česká Republika, Czechia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NS10285
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.